Journal of Translational Internal Medicine最新文献

{"title":"Circular RNA: A promising new star of vaccine.","authors":"Jindong Xie, Fengxi Ye, Xinpei Deng, Yuhui Tang, Jie-Ying Liang, Xufeng Huang, Yuying Sun, Hailin Tang, Jinsong Lei, Shaoquan Zheng, Yutian Zou","doi":"10.2478/jtim-2023-0122","DOIUrl":"10.2478/jtim-2023-0122","url":null,"abstract":"<p><p>Circular RNAs (circRNAs) are a class of single-stranded RNAs with covalently closed structures. Owing to their not having 3' or 5' ends, circRNAs are highly durable and insusceptible to exonuclease-mediated degradation. Moreover, some circRNAs with certain structures are translatable, making them novel vaccines. Vaccines are efficient tools for immunotherapy, such as for the prevention of infectious diseases and cancer treatment. The immune system is activated during immunotherapy to fight against abnormal allies or invaders. CircRNA vaccines represent a potential new avenue in the vaccine era. Recently, several circRNA vaccines have been synthesized and tested <i>in vitro</i> and <i>in vivo</i>. Our review briefly introduces the current understanding of the biology and function of translatable circRNAs, molecular biology, synthetic methods, delivery of circRNA, and current circRNA vaccines. We also discussed the challenges and future directions in the field by summarizing the developments in circRNA vaccines in the past few years.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 4","pages":"372-381"},"PeriodicalIF":4.9,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138835947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term duration of diabetic retinopathy as a predictor for development of diabetic kidney disease.","authors":"Jiayu Duan, Dongwei Liu, Zihao Zhao, Lulu Liang, Shaokang Pan, Fei Tian, Pei Yu, Guangpu Li, Zhangsuo Liu","doi":"10.2478/jtim-2022-0074","DOIUrl":"10.2478/jtim-2022-0074","url":null,"abstract":"<p><strong>Background: </strong>Diabetic retinopathy (DR) is a risk factor for diabetic kidney disease (DKD). Whether the duration, especially the short-term duration, of DR is associated with the development and progression of DKD remains unclear.</p><p><strong>Materials and methods: </strong>A retrospective study and two-sample Mendelian randomization (MR) analysis were conducted. Kidney disease was defined by the urinary albumin-to-creatinine ratio (ACR) and the estimated glomerular filtration rate (eGFR). DR was diagnosed by an expert ophthalmologist by using a digital fundus camera. Binary and ordinal logistic regression analyses were performed. A restricted cubic spline was utilized to detect nonlinear associations. Summary statistics for DR- and DKD-associated single-nuclear polymorphisms (SNPs) were extracted from the FinnGen and the UK Biobank consortia.</p><p><strong>Results: </strong>A total of 2674 patients with type 2 diabetes mellitus (T2DM) and type 2 diabetic kidney disease (T2DKD) were included. The prevalence and mean duration of DR increased with elevation of ACR and decline in eGFR. Renal function was significantly reduced in patients with DR in the fifth year of life. Binary and ordinal logistic regression showed that each 1-year increase in DR duration was associated with a 19% risk increase in the development of DKD, 16% in the elevation of ACR, and 21% in the decline of renal function. MR estimates indicated that DR was causally associated with DKD development, with an odds ratio of 2.89.</p><p><strong>Conclusions: </strong>DR and the duration of DR were independent risk factors for the development and progression of DKD. The short-term duration of DR may be associated with DKD development. DR had a statistically significant effect on DKD.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 4","pages":"449-458"},"PeriodicalIF":4.9,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trend of acute myocardial infarction-related mortality and associated racial/ethnic disparities during the omicron outbreak.","authors":"Yee Hui Yeo, Yue Zhang, Xinyuan He, Fan Lv, Jignesh K Patel, Fanpu Ji, Susan Cheng","doi":"10.2478/jtim-2023-0125","DOIUrl":"10.2478/jtim-2023-0125","url":null,"abstract":"","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 4","pages":"468-470"},"PeriodicalIF":4.9,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial.","authors":"Hu Zhou, Shouqing Han, Jie Jin, Ruibin Huang, Xinhong Guo, Xuliang Shen, Binghua Wang, Xin Wang, Hongxia Yao, Xin Du, Meijuan Huang, Xuehong Ran, Wei Wang, Tonghua Yang, Feng Zhang, Changcheng Zheng, Xuelan Zuo, Rong Fu, Da Gao, Zheng Ge, Ying Han, Yujie Li, Xiaoyan Kang, Yan Shi, Ming Hou","doi":"10.2478/jtim-2023-0106","DOIUrl":"10.2478/jtim-2023-0106","url":null,"abstract":"<p><strong>Objective: </strong>QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein, is a romiplostim (Nplate^®) biosimilar used to treat primary immune thrombocytopenia (ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adult patients with chronic primary ITP over a 24-week treatment period.</p><p><strong>Methods: </strong>We conducted a double-blind, placebo-controlled, phase III study in patients diagnosed with primary ITP for at least 12 months who had received at least one first-line ITP treatment with no response or recurrence after treatment, or who relapsed after splenectomy at 44 sites in China. Patients were randomly allocated (2:1 ratio) to QL0911 or placebo injection subcutaneously once weekly at an initial dose of 1 μg/kg for 24 weeks. The doses were adjusted to maintain the target platelet counts from 50 × 109/L to 200 × 109/L. Patients and investigators were blinded to the assignment. The primary endpoints were the proportion of patients who achieved a durable platelet response at week 24 (platelet count, ≥ 50 × 109/L during 6 of the last 8 weeks of treatment) and safety. The study was registered at ClinicalTrials.gov (NCT05621330).</p><p><strong>Results: </strong>Between October 2019 and December 2021, 216 patients were randomly assigned (QL0911,144; placebo,72). A durable platelet response was achieved by significantly more patients in the QL0911 group (61.8%, 95% CI: 53.3-69.8; <i>P</i> < 0.0001) than in the placebo group (0%). The mean duration of platelet responses was 15.9 (SE: 0.43) weeks with QL0911, and 1.9 (SE:0.26) week with placebo. Consistent results were achieved in subgroup analyses categorized by baseline splenectomy status (yes/no), concomitant ITP treatment (yes/no), and baseline platelet count (≤ 10 × 109/L, > 10 × 109/L, ≤ 20 × 109/L, > 20 × 109/L, and < 30 × 109/L). The incidence of TEAEs was comparable between the QL0911 and the placebo groups (91.7% and 88.9%, respectively). The most common adverse events overall were ecchymosis (28.5% for QL0911 <i>vs</i>. 37.5% for placebo), upper respiratory tract infections respiratory tract infections (31.9% for QL0911 <i>vs</i>. 27.8% for placebo), and gingival bleeding (17.4% for QL0911 <i>vs</i>. 26.4% for placebo).</p><p><strong>Conclusion: </strong>QL0911 was well-tolerated and increased and maintained platelet counts in adults with ITP. QL0911, a biosimilar to romiplostim (Nplate®), may be a novel treatment option for patients with ITP who have failed or relapsed from first-line treatment in China. Ongoing studies will provide further data on long-term efficacy and safety in such patient populations.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 4","pages":"423-432"},"PeriodicalIF":4.9,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of TIPS for the management of portal vein thrombosis in liver cirrhosis.","authors":"Yong Lv, Yanglin Pan, Huahong Xie, Changbing Yang, Daiming Fan, Guohong Han","doi":"10.2478/jtim-2023-0095","DOIUrl":"10.2478/jtim-2023-0095","url":null,"abstract":"","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 4","pages":"316-319"},"PeriodicalIF":4.9,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of esophageal and gastric cancer patients with cardiovascular and metabolic diseases: A two-center propensity score-matched cohort study.","authors":"Bo Zhou,&nbsp;Zhixin Wang,&nbsp;Qifeng Dou,&nbsp;Wenbin Li,&nbsp;Yangyang Li,&nbsp;Zhengqiang Yan,&nbsp;Peisheng Sun,&nbsp;Baosheng Zhao,&nbsp;Xiumin Li,&nbsp;Fangfang Shen,&nbsp;Bangjie Zhang,&nbsp;Mingzhou Guo","doi":"10.2478/jtim-2023-0112","DOIUrl":"10.2478/jtim-2023-0112","url":null,"abstract":"<p><strong>Background and objectives: </strong>An increased risk of cardiovascular and metabolic diseases (CVMDs) among patients with cancer suggests a potential link between CVMD and cancer. The impact of CVMD on the survival time of patients with esophageal and gastric cancer remains unknown. We aimed to determine the incidence of CVMD and its impact on the longterm outcomes in esophageal and gastric cancer patients.</p><p><strong>Methods: </strong>A total of 2074 cancer patients were enrolled from January 1, 2007 to December 31, 2017 in two hospitals, including 1205 cases of esophageal cancer and 869 cases of gastric cancer, who were followed up for a median of 79.8 and 79.3 months, respectively. Survival time was analyzed using the Kaplan-Meier method before and after propensity score matching.</p><p><strong>Results: </strong>The incidence of CVMD in patients with esophageal and gastric cancer was 34.1% (411/1205) and 34.3% (298/869), respectively. The effects of hypertension, diabetes, and stroke on the long-term survival of esophageal and gastric cancer patients were not significant (all <i>P</i> > 0.05). The survival time was significantly longer in esophageal cancer patients without ischemic heart disease than in patients with ischemic heart disease, both before matching (36.5 <i>vs.</i> 29.1 months, <i>P</i> = 0.027) and after matching (37.4 <i>vs.</i> 27.9 months, <i>P</i> = 0.011). The survival time in gastric cancer patients without ischemic heart disease was significantly longer than in patients with ischemic heart disease, both before (28.4 <i>vs.</i>17.5 months, <i>P</i> = 0.032) and after matching (29.5 <i>vs.</i>17.5 months, <i>P</i> = 0.02).</p><p><strong>Conclusion: </strong>The survival time of esophageal and gastric cancer patients with ischemic heart disease was significantly reduced compared to that of esophageal and gastric cancer patients without ischemic heart disease.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"234-245"},"PeriodicalIF":4.9,"publicationDate":"2023-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41219785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total and individual PBC-40 scores are reliable for the assessment of health-related quality of life in Greek patients with primary biliary cholangitis.","authors":"Eirini I Rigopoulou,&nbsp;Marianna Bakarozi,&nbsp;Ioannis Dimas,&nbsp;Konstantinos Galanis,&nbsp;Vasiliki Lygoura,&nbsp;Nikolaos K Gatselis,&nbsp;Mairi Koulentaki,&nbsp;George N Dalekos","doi":"10.2478/jtim-2023-0098","DOIUrl":"https://doi.org/10.2478/jtim-2023-0098","url":null,"abstract":"<p><strong>Background: </strong>Primary biliary cholangitis (PBC) has been long associated with impairment of various aspects of health-related quality of life (HRQoL) with substantial differences among populations. This study evaluated for the first-time the HRQoL in Greek PBC patients in conjunction with clinical and laboratory parameters of patients.</p><p><strong>Methods: </strong>We analyzed prospectively collected data regarding the HRQoL by using the PBC-40 and SF-36 questionnaires in 374 Greek PBC patients and 131 age- and sex-matched non-PBC controls.</p><p><strong>Results: </strong>The PBC-40 questionnaire is a reliable tool for HRQoL assessment in Greek PBC patients (Cronbach's α > 0.7 for all domains). Implementation of PBC-40 and SF-36 demonstrated significant impairment of HRQoL in Greek PBC patients compared to controls (<i>P</i> < 0.001 for all comparisons). Emotional dysfunction, social impairment, and fatigue (100%, 80.5% and 78%, respectively) were amongst those with the highest, while cognitive dysfunction (32%) with the least impact on quality of life. Fatigue was associated with female sex (<i>P</i> = 0.02), longer disease duration (<i>P</i> = 0.01), presence of cirrhosis (<i>P</i> = 0.02) and positivity for PBC-specific ANA (<i>P</i> < 0.05), while social dysfunction with increased age (<i>P</i> < 0.001), longer disease duration (<i>P</i> < 0.001) and presence of cirrhosis (<i>P</i> = 0.004). Living in urban areas was linked to impaired social function (<i>P</i> = 0.04), cognition (<i>P</i> = 0.02), fatigue (<i>P</i> = 0.04) and increased total PBC-40 score (<i>P</i> = 0.01).</p><p><strong>Conclusions: </strong>Implementation of PBC-40 and SF-36 revealed impaired HRQoL in Greek PBC patients with fatigue, social and emotional dysfunction exerting the highest impact. However, total, and individual PBC-40 scores were lower than that reported in studies from Northern/Central Europe and Canada. Deranged HRQoL was associated with severity of liver disease and presence of PBC-specific ANA.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"246-254"},"PeriodicalIF":4.9,"publicationDate":"2023-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41219786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic stress-induced immune dysregulation in breast cancer: Implications of psychosocial factors.","authors":"Xiuyun Chen,&nbsp;Mozhi Wang,&nbsp;Keda Yu,&nbsp;Shouping Xu,&nbsp;Pengfei Qiu,&nbsp;Zhidong Lyu,&nbsp;Xinwen Zhang,&nbsp;Yingying Xu","doi":"10.2478/jtim-2021-0050","DOIUrl":"https://doi.org/10.2478/jtim-2021-0050","url":null,"abstract":"<p><p>Chronic stress refers to continuous emotional changes and psychological pressure that individuals experience when they are unable to adjust and stabilize the internal environment over an extended period. It can increase the pressure on endocrine mediators and cytokines in the circulation, as well as tissues throughout the hypothalamic-pituitary-adrenaline (HPA) axis and sympathetic nervous system (SNS); thus, evolving the internal environment of the tumor. This review assesses several key issues, involving psychosocial factors, and integrates clinical, cellular, and molecular studies-as well as the latest research progress-to provide a mechanistic understanding regarding breast oncopsychology. We propose that chronic stress contributes to large individual diferences in the prognosis of breast cancer survivors because they change the basic physiological processes of the endocrine and immune systems, which in turn regulate tumor growth. The study of psychological and physiological reactions of breast cancer patients suggests a new idea for psychological intervention and clinical treatment for breast cancer patients.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"226-233"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10208195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiR-182/Sestrin2 affects the function of asthmatic airway smooth muscle cells by the AMPK/mTOR pathway.","authors":"Yali Xiao,&nbsp;He Zhu,&nbsp;Jiahui Lei,&nbsp;Jing Xie,&nbsp;Ke Wu,&nbsp;Wenbo Gu,&nbsp;Jinxin Ma,&nbsp;Dongxue Wei,&nbsp;Zhenhui Shu,&nbsp;Limin Zhao","doi":"10.2478/jtim-2023-0108","DOIUrl":"https://doi.org/10.2478/jtim-2023-0108","url":null,"abstract":"<p><strong>Background and objectives: </strong>Asthma is a chronic inflammatory airway disease and brings heavy economic and spiritual burdens to patients' families and the society. Airway smooth muscle cells (ASMCs) afect the development of asthma by secreting cytokines, growth factors, and prostates. The stress-inducing protein, Sestrin2, plays a vital role in antioxidant defense. The aim of this study is to investigate the role of Sestrin2 in asthma and its corresponding molecular mechanism.</p><p><strong>Materials and methods: </strong>Airway remodeling was induced by construction of asthma rat model. Primary ASMCs were isolated through combining tissue block adherence and enzymatic digestion and identified by immunofluorescence staining. Gene expression was measured by quantitative real-time PCR (qPCR) and western blot (WB) experiments. Cell viability, proliferation, migration, and calcium flow of ASMCs were measured by Cell Counting Kit-8 (CCK-8), 5-ethynyl-deoxyuridine (EdU), Transwell, and Fluo-3AM, respectively. The binding of miR-182 and Sestrin2 3'-untranslated region (3'-UTR) was measured by luciferase reporter system and RNA-binding protein immunoprecipitation (RIP) analysis.</p><p><strong>Results: </strong>Sestrin2 expression was upregulated in asthma rat model and cell model. Overexpression of Sestrin2 enhanced the growth, migration, and calcium flow, and inversely, repression of Sestrin2 was reduced in ASMCs from the asthma group. MiR-182, one of the microRNAs (miRNAs) that possesses the potential to regulate Sestrin2, was downregulated in ASMCs from the asthma group. Further experiments revealed that Sestrin2 was inhibited by miR-182 and that overexpression of Sestrin2 reversed the miR-182-induced inhibition of the cellular progression of ASMCs from the asthma group. This study further investigated the downstream signaling pathway of Sestrin2 and found that increased expression of Sestrin2 activated 5'-adenosine monophosphate-activated protein kinase (AMPK), leading to the inactivation of mammalian target of rapamycin (mTOR) and thus promoting the growth, migration, and calcium flow of ASMCs from the asthma group.</p><p><strong>Conclusion: </strong>This study investigated the role of Sestrin2 for the first time and further dissected the regulatory factor of Sestrin2, ultimately elucidating the downstream signaling pathway of Sestrin2 in asthma, providing a novel pathway, and improving the understanding of the development and progression of asthma.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"282-293"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10293021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network-guided neuromodulation for epilepsy: Unveiling the pathway to personalized therapy.","authors":"Peng Cao,&nbsp;Shun Gong,&nbsp;Liang Liu,&nbsp;Guobiao Liang","doi":"10.2478/jtim-2023-0101","DOIUrl":"https://doi.org/10.2478/jtim-2023-0101","url":null,"abstract":"Epilepsy, a chronic neurological disorder characterized by recurrent seizures, affects millions of individuals worldwide. Despite advancements in antiepileptic drugs and surgical interventions, a significant portion of patients continue to experience uncontrolled seizures, leading to a reduced quality of life. In recent years, the intersection of network neuroscience and neuromodulation has opened up promising avenues for personalized and targeted therapies for epilepsy. This editorial aims to synthesize and discuss the findings from multiple studies[1-4] that shed light on the role of specific brain regions in the epileptogenic network and their potential as neuromodulation targets. They have revealed that modulating specific brain regions within the epileptogenic network can yield therapeutic benefits for epilepsy patients. Multiple targets have been explored, including the anterior nucleus of the thalamus (ANT), the hippocampus, the subthalamic nucleus (STN), the cerebellum, and others. Each of these regions has unique connections with cortical and subcortical structures, making them potential nodes for seizure propagation.","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"203-205"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10524599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}